SCYNEXIS, Inc. (LON:0L49)

Market Cap	33.91M
Revenue (ttm)	2.38M
Net Income (ttm)	-14.25M
Shares Out	n/a
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,280
Average Volume	4,782
Open	1.260
Previous Close	1.189
Day's Range	1.210 - 1.290
52-Week Range	0.660 - 1.640
Beta	n/a
RSI	63.39
Earnings Date	Nov 13, 2025

About SCYNEXIS

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has lic...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 28
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0L49

Financial Performance

Financial numbers in USD